Cancer and Total Hip Replacement. Cancer as a risk factor for prosthesis and prosthesis as a risk factor for cancer by Dybvik, Eva Hansen
Dissertation for the degree of philosophiae doctor (PhD)  
at the University of Bergen 
Dissertation date: 
&DQFHUDQG7RWDO+LS5HSODFHPHQW
&DQFHUDVDULVNIDFWRUIRUSURVWKHVLVDQGSURVWKHVLVDVDULVN
IDFWRUIRUFDQFHU
(YD+DQVHQ'\EYLN


© Copyright Eva Hansen Dybvik 
The material in this publication is protected by copyright law. 
Year: 2015 
Title: Cancer and Total Hip Replacement 
Cancer as a risk factor for prosthesis and prosthesis as a risk factor for cancer 
Author: Eva Hansen Dybvik 
Printed by: AIT OSLO AS / University of Bergen 
3 
Scientific environment 
This thesis is based on data from the Cancer Register of Norway and the Norwegian 
Arthroplasty Register. 
The study was initiated in 2006 while the author was working as a biostatistician at 
the Norwegian Arthroplasty Register. From August 2007, three-year full-time 
financial support was provided by the Western Norway Regional Health Authority. 
The last period was financed by the Norwegian Arthroplasty Register. 
Supervision has been provided by staff of the Norwegian Arthroplasty Register at the 
Department of Orthopedic Surgery, Haukeland University Hospital, staff of the 
Department of Clinical Dentistry and the Department of Clinical Medicine at the 
University of Bergen and staff of the National Advisory Unit on Late Effects after 
Cancer Treatment at the Norwegian Radium Hospital, Oslo University Hospital.  
As many as 19 candidates have taken PhD degrees based on data from the Norwegian 
Arthroplasty Register since its initiation in 1987. 
This thesis is a part of the PhD programme at the Department of Clinical Medicine, 
University of Bergen.  
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2. Abstract 
Annually, 14 million new cancer cases are detected worldwide; the numbers are 
expected to rise by 70% over the next decades. In Norway, 30,000 new cancer cases 
are detected every year. Because of screenings and increased attention to cancer in 
the population, more cancer cases are detected at an early stage and a higher number 
of cancer diagnoses are detected. Results of better and earlier treatment are that 
patients survive and continue to live for many years after a cancer diagnosis. 
In Western countries, total hip replacements have become a common treatment for 
hip joint disease and injury.  Standards of living have risen and people are living 
longer, hence Western populations have an increased proportion of elderly people. 
Better anaesthetics, lower risks associated with surgery and better quality of 
prostheses enable both younger and older patients with good general health to receive 
total hip replacements. In Norway almost 8,000 primary total hip replacement 
operations are performed annually. 
All papers in this thesis are based on a linkage between the Cancer Registry of 
Norway and the Norwegian Arthroplasty Register. 
In this thesis there are two different aspects. The first aspect is the cancer patients; if 
they survive cancer and live on for many years, there is a risk for developing other 
diseases and disorders. These may be late effects related to the treatment they 
received for cancer. In this thesis we consider damage to bone and cartilage in the 
hip. Our outcome measurement is the insertion of a total hip replacement. 
The second aspect is the patients who have received a total hip replacement. Could 
insertion of metal prosthesis with or without bone cement in the hip joint increase the 
patient's risk for late development of cancer? 
In Paper 1 we selected cancer patients who were 16-90 years old when their first 
cancer was diagnosed, had no hip replacement prior to the cancer diagnosis and were 
alive when the Norwegian Arthroplasty Register started registration (September 
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1987). We compared the observed hip replacement patients with incidence in the 
general population. Cancer patients were divided in groups according to the location 
of the cancer and compared. We found an increased risk for hip replacement for 
patients with lymphoma malignancies and cancer in the pelvic area. 
In Paper 2 we selected two groups of cancer patients to investigate whether radiation 
to the pelvic area increased the risk for total hip replacement. We included women 
only; one group consisted of patients with gynaecological cancer and radiation to the 
pelvic area while the other group consisted of breast cancer patients with radiation to 
the breast and not to the pelvic area. The mortality differed greatly in the two groups, 
so we used competing risk models to estimate the risk for receiving prosthesis. We 
found no statistically increased risk for hip replacements for patients with 
gynaecological cancer compared to patients with breast cancer. 
In Paper 3 we selected patients with total hip replacement. We compared their cancer 
risk to the general population in Norway. We also used Cox models and competing 
risk models with time-dependent covariates to compare different prosthesis fixations. 
We found an increased risk of cancer for patients with uncemented total hip 
replacement compared to patients with cemented total hip replacement. Patients with 
a combination of cemented cup and uncemented stem (reversed hybrid) had a similar 
risk for cancer as those with uncemented prosthesis. 
The overall conclusion in this thesis is that we found a relation between cancer and 
total hip replacements. There seems to be an increased risk for hip replacements for 
some cancer types, but we could not find any increased risk due to irradiation of the 
hips. For patients who have had a hip replacement for more than 10 years, 
uncemented prosthesis seems to increase the risk of cancer.  
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3. Norsk sammendrag 
På verdensbasis oppdages årlig 14 millioner nye krefttilfeller, antallet er også 
forventet å stige med opp til 70 % de neste tiårene. I Norge oppdages rundt 30 tusen 
nye krefttilfeller i året. På grunn av screeninger og økt fokus på kreft i befolkningen 
blir flere krefttilfeller oppdaget på et tidlig stadium, dette fører til en økning i antall 
kreftdiagnoser. Behandlingen kan starte tidlig og flere av pasientene overlever og 
fortsetter å leve i mange år etter en kreftdiagnose.  
I den vestlige verden har totale hofteproteser blitt en vanlig behandling for sykdom 
og skade i hofteleddet. Levestandarden har gått opp og folk lever lengre, dermed er 
det en større andel eldre i befolkningen. Bedre anestesi, lavere risiko forbundet med 
operasjonen og ikke minst bedre kvalitet på protesene gjør at både yngre pasienter og 
eldre pasienter med god allmenn helsetilstand kan få satt inn hofteproteser. I Norge 
settes det inn i underkant av 8 tusen primære hofteproteser i året. 
Alle artiklene i denne avhandlingen er basert på kobling mellom Kreftregisteret og 
Nasjonalt register for leddproteser.  
I denne avhandlingen har vi to ulike aspekter. Først kan man se på kreftpasientene, 
hvis de overlever kreften og lever i mange år kan de senere utvikle andre sykdommer 
og lidelser. Dette kan være seneffekter relatert til behandlingen de fikk for kreft. I 
denne avhandlingen ser vi på skader relatert til skjelettet og brusken, nærmere 
bestemt i hofteleddet. Vårt endepunkt var innsetting av total hofteprotese. 
På den andre siden kan man se på pasientene som har fått hofteprotese. Kan 
innsetting av metallprotese med eller uten bensement i hoften øke pasientens risiko 
for å få kreft på et senere tidspunkt?   
I Artikkel 1 har vi sett på kreftpasientene. Vi inkluderte pasienter som var 16-90 år da 
de fikk første kreftdiagnose, de måtte ikke ha protese før kreftdiagnosen og de måtte 
være i live når Leddregisteret startet (september 1987). Vi sammenlignet de 
observerte protesetilfellene med insidenstall fra befolkningen. Kreftpasientene ble 
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delt inn etter lokaliseringen av kreften og disse gruppene ble sammenlignet med 
hverandre. Vi fant økt risiko for å få hofteprotese for pasienter med lymfekreft og 
kreft i bekkenregionen.  
I Artikkel 2 har vi valgt ut to grupper med kreftpasienter for å undersøke om stråling 
mot bekkenregionen gir økt risiko for hofteprotese. Vi inkluderte kun kvinner i 
studien, den ene gruppen bestod av pasienter med gynekologisk kreft og stråling mot 
bekkenregionen mens den andre gruppen bestod av brystkreftpasienter med stråling 
mot brystene men ikke stråling i bekkenregionen. Det var stor forskjell i dødelighet 
mellom gruppene, så vi brukte en competing risk modell for å beregne risikoen for å 
få protese. Vi fant ingen statistisk økt risiko for hofteproteser for pasientene med 
gynekologisk kreft sammenlignet med pasientene med brystkreft. 
I Artikkel 3 har vi sett på protesepasientene. Vi sammenlignet deres kreftrisiko med 
den generelle befolkningen i Norge. I tillegg brukte vi Cox modeller og competing 
risk modeller med tidsavhengige kovariater for å sammenligne ulike 
operasjonsmetoder. Vi fant en økt risiko for kreft for pasienter med usementerte 
hofteproteser sammenlignet med pasienter med sementerte hofteproteser. Pasienter 
med en kombinasjon av sementert kopp og usementert stamme (omvendt hybrid) 
hadde samme risiko for kreft som pasienter med usementerte hofteproteser. 
Hovedfunnet i denne avhandlingen er at vi finner en sammenheng mellom kreft og 
hofteproteser. Det ser ut som om det er en økt risiko for hofteproteser etter enkelte 
krefttyper, men vi fant ingen effekt i risikoen etter strålebehandling. For pasienter 
som har hatt en hofteprotese i mer enn 10 år ser det ut som en usementert 
hofteprotese øker risikoen for kreft. 
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4. List of Abbreviations 
CI   Confidence Interval 
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ICD   International Classification of Diseases 
IRR   Incidence Rate Ratio 
NAR   Norwegian Arthroplasty Register 
RCT   Randomized Clinical Trial 
RR   Relative Risk 
SIR   Standardized Incidence Ratio 
SHR   Sub Hazard Ratio 
THA   Total Hip Arthroplasty (synonym of THR)   
THR   Total Hip Replacement (used in this thesis) 
TKA/TKR  Total Knee Arthroplasty/Replacement 
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6. Introduction and background 
Epidemiology is derived from Greek epi, demos and logos. Epi means “upon, 
among”, demos means “people, district” and logos means “study, word, discourse”. 
Epidemiology then becomes “the study of what is upon the people”. 
Epidemiology is the branch of medicine which deals with the incidence, distribution, 
and possible control of diseases and other factors relating to health and also studies 
the relationship between diseases and risk factors. 
6.1 Cancer 
Hippocrates, known as the ‘Father of Medicine’ (460-370 BC) used the Greek word 
carcinos (crab) and carcinoma to describe tumours and swellings. Most likely it was 
the crab-like appearance of the disease that gave rise to the name. A Roman 
physician, Celsus (25 BC-50 AD) translated the word into cancer, the Latin word for 
crab. A Greek physician, Galen (130-200 AD) used the word oncos (Greek for 
swelling) to describe tumours, and today this word is used as a part of the word for 
cancer specialists – oncologists (American Cancer Society 2015, David and 
Zimmerman 2010, Sudhakar 2009). 
 
Figure 1: Illustrated cancer cells and Brown crab (cancer pagurus). 
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But even though Hippocrates came up with a name, he was not the first to discover 
the disease. Cancer had already been described in an ancient Egyptian textbook on 
trauma surgery, dating back to about 3000 BC. Cancer has been identified in 
skeletons from Egypt from the period between 3200 and 500 BC (Nerlich et al. 2006, 
Sudhakar 2009). Hence, cancer is not a modern disease. 
Cancer is a group of diseases characterized by uncontrolled growth of abnormal cells 
in the body. When the body’s normal control mechanism stops working, cancer can 
develop. Old cells do not die and cells grow out of control, forming new abnormal 
cells. These cells have the ability to form a mass of tissue, called tumour. The cells 
can invade the surrounding organs, and also have the ability to provide secondary 
tumours elsewhere in the body. Benign tumours consisting of normal cells are not 
considered cancer; they are often limited by normal tissue and usually stop growing 
after a while, in contrast to malignant tumours that will continue to grow and may 
eventually do serious damage to nearby tissues and organs (American Cancer Society 
2015, Sudhakar 2009).  
Cancer can occur anywhere in the body. In men, prostate cancer is the most common 
cancer, while for women breast cancer is the most common. Colorectal cancer and 
lung cancer affect both genders in high numbers (Bray et al. 2013, Cancer Registry of 
Norway 2015). 
The public health care system in Norway provides cancer treatment and follow-up, 
free of charge, for all citizens irrespective of social and economic status (Molven and 
Ferkis 2011). The three main treatments are surgery, chemotherapy and radiation 
therapy. In surgery the tumours are directly removed, while in chemotherapy 
chemicals are used to kill the cancer cells. In radiation therapy X-ray beams are used 
to radiate and to kill cancer cells. Treatment of a patient may consist of a combination 
of these three methods.  
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Figure 2:  A – Surgery: removing a sarcoma from the upper thigh, B - chemotherapy 
drugs, C – radiation to the pelvic area.  
Lifetime risk of cancer reflects the probability of being diagnosed with cancer in the 
course of one’s lifespan. Lifetime risk is widely used as a scale of how widespread 
cancer is in a specific population. In Norway the lifetime risk is 35.9% for men and 
28.8% for women (Cancer Registry of Norway 2015). The United States has a 
lifetime risk for men of 43.2% and for women 37.8% (Howlader et al. 2014). In Great 
Britain they have estimated the future risks and calculated the lifetime risk of cancer 
for people born since 1960 to be higher than 50% (Ahmad et al. 2015, Tanday 2015).  
Worldwide, cancer is one of the leading causes of mortality and morbidity and the 
incidence has increased from 12.7 million new cases in 2008 to 14.1 million new 
cases in 2012 (World Health Organization 2014). Cancer caused 8.2 million deaths in 
2012, which was 14.6% of all deaths worldwide. It is expected that annual cancer 
cases will rise from 14 million in 2012 to 22 million within the next two decades. In 
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Norway, 30,401 new cases of cancer and 10,699 deaths from cancer were recorded in 
2013 (Cancer Registry of Norway 2015).  
The reason for the increased number of cancers may be an increase in diagnosed 
patients due to screening, increased attention to cancer in the population and among 
health care providers, reduced mortality for competing diseases (e.g. coronary heart 
diseases) and increased life expectancy. The reduced mortality of cancer can 
furthermore be related to improved treatment. Some authors claim that there are other 
mechanisms for the increase of cancer and reduced mortalities (Zahl et al. 2013, Zahl 
and Maehlen 2012). 
The cause of cancer has been discussed; a recent report showed that two out of three 
cancer cases are the result of biological bad luck (Tomasetti and Vogelstein 2015). 
This was based on a strong correlation between lifetime risk for different cancer types 
and numbers of divisions of stem cells in different organs. Hence, environmental 
factors or inherited predispositions are associated with only one-third of cancer 
episodes. Several researchers have questioned those analyses and the results 
(Andreassen et al. 2015, Couzin-Frankel 2015, Potter and Prentice 2015, Wodarz and 
Zauber 2015). A group from the Cancer Registry of Norway pointed out that cancer 
types used by Tomasetti and Vogelstein only covered about 50% of all cancer cases 
in Norway, and the most common types like breast and prostate cancer were not 
included (Andreassen et al. 2015). 
Not all cancers can be prevented, but a large part of current cancer cases could be 
avoided with appropriate precautions. Tobacco, overweight and obesity, physical 
inactivity and diet are the modifiable causes of cancer that generate the most disease 
(Colditz et al. 2012, Parkin et al. 2011). Both society and individuals could contribute 
to lowering individuals’ cancer risk.   
The number or proportion of individuals in a population who have previously 
received a diagnosis of cancer and who are still alive at a given point in time is 
defined as the cancer prevalence. Worldwide, at the end of 2012, almost 32.5 million 
people diagnosed with cancer had survived more than five years (World Health 
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Organization 2014). When patients survive for many years after a cancer diagnosis, 
the risk for other diseases increases. These diseases could be late effects related to the 
treatment the patients received for the cancer. After five years, approximately two-
thirds of cancer patients are still alive (Sant et al. 2009). Research on late adverse 
effects in cancer survivors has gained increasing interest over the last decade. 
However, the main interest has been on secondary cancer events (Curtis et al. 2006), 
cardiovascular complications and emotional problems (Meyerowitz et al. 2008). 
Skeletal adverse effects of irradiation include cell death, cellular injury and abnormal 
bone repair, although the underlying mechanisms are not fully understood (Yurut-
Caloglu et al. 2010). 
Radiation and chemotherapy for cancer may negatively influence the normal bone 
formation and thereby give rise to structural and functional alterations of the skeleton 
and joints. Radiation therapy directed at the pelvic region may damage bone 
structures or bone repair in the hip (Fu et al. 1994), through an imbalance of – or 
reduced activity in – osteoclasts and osteoblasts. Based on bone scan images, 
osteoblast activity within a radiation field is reduced for several years after radiation 
(Fosså and Winderen 1993). Also long-term treatment with corticosteroids, as used in 
childhood cancer and Hodgkin’s lymphoma, will reduce osteoblast activity and thus 
increase the risk of osteoporotic fractures (van der Sluis and van den Heuvel-Eibrink 
2008). Premature menopause in patients with gynaecological cancers or breast 
cancer, chemotherapy and aromatase inhibitors are associated with an increased risk 
of osteoporosis (Molina et al. 2005, Yamamoto and Iwase 2008) as is androgen 
deprivation therapy in men with prostate cancer (Israeli et al. 2008). It has been 
shown that high-dose pelvic irradiation is followed by micro-fractures in the sacrum 
(Herman et al. 2009). Similar bone alterations may occur in the hips, which are 
irradiated using the box technique of pelvic malignancies. In addition to the primary 
alterations of irradiated bone, radiotherapy of soft tissues around major joints may 
result in increased fibrosis and sciatic changes, leading to abnormal functional 
conditions with premature development of arthrosis (Goitz et al. 2007).  
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Hence, a hip replacement may represent an excellent modality of palliative treatment 
in selected patients, with metastatic spread to the hip. All these conditions may also 
lead to an increased risk of hip fractures which may require hip prostheses. 
 
Figure 3: X-ray showing a radiation-induced pelvic osteoporosis on the patient’s left 
side; such osteoporosis may cause a failed hip and the need for a THR. 
6.2 Total Hip Replacement (THR) 
In 1890 the first total joint replacement was performed by Gluck in Berlin; a 
tuberculous knee joint of a 17 year old girl was replaced by an ivory replacement 
(Brand et al. 2011, Eynon-Lewis et al. 1992, Gluck 1891). Gluck had remarkably 
successful short term results with ivory replacements in knee, wrist, elbow, shoulder, 
ankle and hip. But they all failed because of chronic infection. Another pioneer, 
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Jules-Émile Péan, designed a shoulder prosthesis made of platinum and leather in 
1893. After two years the implant was removed because of chronic infection (Lugli 
1978, Péan 1894). Norwegian born Marius Nygaard Smith-Petersen developed mould 
arthroplasty of the hip, in 1923 using glass and in 1938 using cobalt chromium, to 
cover the head of the femur (Smith-Petersen 1948, Smith Petersen 1939). The Smith-
Petersen resurfacing hip was the usual hip replacement of the 1940s and 1950s. Other 
pioneers around the early 1950s were the Judet brothers from France, Haboush, Urist 
and McBride from the United States and McKee, Farrer and Ring from England. All 
of them made pioneering steps towards long-term beneficial effects of total hip 
arthroplasty (Toledo-Pereyra 2004). In the 1960s, Sir John Charnley introduced a 
new design with cemented low-friction hip arthroplasty (Charnley 1961, Charnley 
1970). Charnley used a cemented polyethylene acetabular component and a cemented 
stainless steel monoblock component with a small stainless steel head (22mm) on the 
femoral side. This was the start of modern hip arthroplasty, and still this design and 
method is used as a reference to which new products are compared. 
A total hip replacement is a major surgery to replace one of the crucial joints of the 
body when disease or injury has caused a painful or destructed joint. More than 70 
different hip diseases were found to be the cause of hip replacement in Norway 
(Furnes et al. 2001). THR has been known to be one of the more successful in terms 
of pain relief and improved functioning, and also cost-efficient operations in modern 
medicine (Daigle et al. 2012, Learmonth et al. 2007). Every year more than 1 million 
arthroplasties are performed worldwide; projections have indicated that this number 
will double within the next two decades (Kurtz et al. 2007, Pivec et al. 2012).  
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Figure 4: A total hip replacement operation. Photo: Yngvar Krukhaug 
Total hip replacements are common in Western countries. In populations with an 
increasing proportion of elderly people, there have been increases in the incidence the 
last decades. In Norway the frequency of primary THR has increased from 109 
operations per 100,000 inhabitants in 1991-95 to 140 operations in 2006-08 
(Espehaug et al. 2011). Similar increases have been documented in all the Nordic 
countries (Lohmander et al. 2006), Australia (Graves et al. 2004), Canada (Canadian 
Joint Replacement Registry 2014) and the United States (Kurtz et al. 2005). 
When a THR is inserted, both the acetabular cartilage and femoral head and neck are 
removed and replaced by an acetabular cup and a femoral component (stem and 
head). Basic concepts of total hip replacements are illustrated in Figure 5. The 
acetabular component (cup) consists either of a single cup (in Norway polyethylene 
cups are mostly used) or a metal cup with inserts (liners) made of polyethylene, 
ceramic or metal. The femoral component could be produced with stem and head as 
one piece, which is called a monoblock prosthesis. The Charnley prosthesis is an 
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example of a historically widely used monoblock prosthesis. Today the most 
commonly used femoral components have separate heads and stems; these are called 
modular prostheses. The cup and the stem can be fixed with or without cement. If the 
cup and the stem components are fixed with cement, it is called a cemented THR. If 
both components are fixed without cement, it is called an uncemented or cementless 
THR. A combination of uncemented cup and cemented stem is known as hybrid 
THR, and a cemented cup combined with an uncemented stem is known as a reverse 
hybrid THR.  
 
Figure 5: Illustration of basic concepts in total hip replacements. Courtesy of Geir 
Hallan. 
On the market there are many different THRs, with different brands and designs, 
using a variety of materials and articulations. The articulation is the sliding surface 
between the femoral head and the acetabular cup. The older prosthesis types 
generally had metal on polyethylene articulation, while newer designs can have a 
ceramic on polyethylene, ceramic on ceramic, ceramic on metal, or metal on metal 
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articulation. Also for the bone cement for fixation of the prosthesis, there exist many 
different brands, some with added antibiotics and some without antibiotics. In all 
bone cement formulations, radiopacity is provided by micron-sized particles of either 
zirconium dioxide (ZrO2) or barium sulphate (BaSO4) (Lewis et al. 2005). For all the 
mentioned components and materials, new products and procedures are being 
introduced continuously.   
There has been a huge variety of metals and other materials, combined with a variety 
of sizes and bearing surfaces, used in THRs over the years. Concerns have been 
raised as to whether the insertion of prosthesis might lead to subsequent malignancies 
(Keel et al. 2001, Lidgren 2008, Mabilleau et al. 2008, Meyskens 2007). A hip 
replacement creates wear debris from the articulating surface and the interfaces, and 
in addition to local responses, debris may spread over the whole body via systemic 
circulation (lymph and blood). Wear particles have been identified in the 
macrophages of liver and spleen (Urban et al. 2000, Urban et al. 2004). However, it is 
not fully determined how wear debris impacts these organs. Metal ions can be 
generated due to crevice (Willert et al. 1996) or galvanic corrosion. These soluble 
metal ions (e.g. aluminium, chromium, vanadium, cobalt and titanium) may bind to 
proteins and disseminate into the surrounding tissues, bloodstream and remote 
organs. Hallab and colleagues have shown an increase of circulating metal following 
joint replacements (Hallab and Jacobs 2009). In a study with implant materials in 
rats, an increased incidence of lymphatic neoplasms was observed (Memoli et al. 
1986). However, the carcinogenic potential of metallic elements used in THRs is 
unknown. Most studies following cancer incidence after THR have not shown an 
increased incidence compared to the age and gender matched population. However, it 
has been shown that comparison to matched population may underestimate cancer 
risk (Kirkeleit et al. 2013). 
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6.3 Personal identity number 
In 1964 a system of unique 11-digit personal identity numbers was introduced in 
Norway (Selmer 1964). The system was in demand from trade and industry to 
simplify salary, taxes and social security schemes for every inhabitant of Norway.  
The 11 digits are composed of six digits representing the date of birth; two digits for 
the day (01-31), two for the month (01-12) and two for the year (00-99), while the 
next three digits are individual numbers within each date of birth, and the last of them 
also indicates gender: an odd number for male and an even number for female. 
Finally, the last two digits are control digits, based on the first nine digits. These are 
calculated using an algorithm to avoid typographical errors when using the system.   
The identity number is used for multiple purposes, such as in banking, insurance, for 
social benefits, police records, health, etc. In principle, information from these 
sources can be linked but this is regulated through strict rules. One example of a 
linkage of multiple sources is a publication by Moster (Moster et al. 2008). 
6.4 Health registries in Norway 
A health registry is a collection of health data stored systematically so that 
information about a single person can be retrieved. 
The Norwegian parliament has established 17 mandatory national health registries to 
maintain national functions. These registries are regulated by law, and they have a 
goal of providing current, reliable and secure information about the population’s 
health and the quality of healthcare (Folkehelseinstituttet 2015). This includes 
information about disease incidence, unexpected changes in incidence patterns such 
as during an epidemic, and knowledge about risk factors and causes of disease. 
Examples of mandatory national health registries are the Medical Birth Registry of 
Norway, Causes of Death Registry, Norwegian Patient Registry and the Cancer 
Registry of Norway. 
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There are about 200 medical health registries in Norway based on consent from the 
patients, 47 of which have official status as national health registries (as of August 
2014). These registries are created to ensure the quality of treatment, but they are also 
used for research, mapping of disease incidence and treatment of patients (Nasjonalt 
servicemiljø for medisinske kvalitetsregistre 2015). These health registries are not 
regulated by law, but they are licensed by the Data Inspectorate based on the consent 
of the patients or linked to the mandatory health registries. Enthusiasts in the 
academic environments have started registers to improve the quality of treatment. 
Examples of such registries are the Cerebral Palsy Register of Norway, Norwegian 
Multiple Sclerosis Register and the Norwegian Arthroplasty Register. 
There are also central health registers that treat health data in pseudonym form 
(Norwegian Prescription Database) or anonymized form (Register of Pregnancy 
Termination, NORM, NOIS) without consent. 
Additionally, there are other data sources, e.g. at the health authorities, such as 
IPLOS which keeps a record of resources used in the healthcare sector. 
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7. Aims of the studies 
The overall objective of this thesis was to investigate the relation between cancer and 
total hip replacements. In Paper 1 and Paper 2, cancer diagnosis was the starting point 
of the study. We wanted to determine if there was an increased risk for THR for 
patients with a cancer diagnosis. In Paper 3, THR was the starting point, and we 
wanted to determine if there was an increased risk for being diagnosed with cancer 
for THR patients. 
 
The three papers had specific aims: 
Paper I: To investigate whether cancer patients have an increased risk of receiving a 
total hip replacement compared to the general population of Norway. 
A further aim was to examine whether different locations of cancer have different 
risks for receiving total hip replacement. 
 
Paper 2: To examine the risk of receiving a total hip replacement for patients with 
cancer in the pelvic area who had been treated with radiation therapy. 
Analyse patients in two cancer groups, one with pelvic irradiation and one without 
pelvic irradiation, and compare their risk for total hip replacements.  
 
Paper 3: To investigate whether patients with a total hip replacement have an 
increased risk for being diagnosed with cancer compared to the general population of 
Norway. 
To examine whether there are differences in cancer risk according to types of 
prosthesis fixations: cemented, uncemented, hybrid and reversed hybrid. 
 29 
8. Data sources 
8.1 Cancer Registry of Norway (CRN) 
The Cancer Registry of Norway (CRN), Institute of Population-based Cancer 
Research, was established in 1951 (Cancer Registry of Norway 2015). This registry is 
one of the oldest national cancer registries in the world. The CRN has proven to be 
very useful for gaining new knowledge through research and for increasing 
information on cancer both nationally and internationally. Combined with the unique 
personal identification number of Norway, the CRN has a huge potential for linkage 
to other data sources and registries. 
The CRN is one of the mandatory national health registries in Norway, regulated by 
law. All hospitals, laboratories and general practitioners in the country are obliged to 
report new cancer cases to the registry within two months. A notification is also sent 
in case of suspicion of cancer, even if a cancer is not verified, and the cancer is not 
diagnosed before autopsy. Hence, in case of doubt, a notification is expected to be 
sent. There are two forms for clinical notifications to the CRN, one for reporting solid 
tumours and one for reporting non-solid tumours (Appendices 5 and 6). These forms 
contain information on primary site, symptoms, stage of disease, basis for the 
diagnosis and primary treatment given to the patient. In addition, hospitals and 
independent laboratories send pathology reports providing histological, cytological or 
autopsy information.  
The CRN receives around 140,000 reports related to cancer illness every year from 
several independent sources. Due to the multiple sources for the reporting of cancer, 
this secures a high grade of completeness of the data in the CRN. Out of the 140,000 
reports, approximately 30,000 are newly diagnosed cancers.  
Competence in diagnostics and treatment within the cancer registry has steadily 
increased since the start of the registry (Larsen et al. 2009). During the last 20 years, 
the cancer registry has started several clinical quality registries for different cancer 
types (e.g. colorectal, prostate, and lung cancer). This has been done in close 
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cooperation with the clinical milieus in Norway. Many of these have been approved 
as national health registries (Nasjonalt servicemiljø for medisinske kvalitetsregistre 
2015). 
More than 232,000 Norwegians with at least one cancer diagnosis at an earlier point 
in life were alive at the end of 2013. For almost all cancer patients, survival has 
improved during the last five decades; this trend is claimed to be partially due to 
improved treatment over time, but also to screening programmes for breast and 
prostate cancer. Furthermore, health care providers and the population in general 
have an increased awareness of cancer, which may lead to higher numbers of 
diagnosed cancers. The CRN is administered as part of the South-Eastern Norway 
Regional Health Authority and is organized as an independent institution under Oslo 
University Hospital Trust. 
8.2 The Norwegian Arthroplasty Register (NAR) 
In hip replacement surgery, the use of undocumented prosthesis has been common. In 
the early 1970s, the Norwegian total hip replacement known as the Christiansen 
prosthesis became popular (Christiansen 1969). The Christiansen prosthesis was used 
for approximately a decade, and more than 10,000 patients in Scandinavia received 
the prosthesis before inferior long-term results were discovered (Sudmann et al. 
1983). This incident was the main reason that members of the Norwegian 
Orthopaedic Association decided to establish the NAR in September 1987 (Havelin et 
al. 1993). From 1994, registration was extended to include arthroplasty also in knee 
and other joints. The Norwegian Cruciate Ligament Register started registration in 
2004, the Norwegian Hip Fracture Register started in 2005, and the Paediatric Hip 
Register started in 2010 (Norwegian Arthroplasty Register 2015). All of these were 
organized under the umbrella of the NAR. The NAR is clinically governed by the 
Norwegian Orthopaedic Association and financed by the Western Norway Regional 
Health Authority and Haukeland University Hospital. In 2002, the Norwegian 
Ministry of Health approved the registry as a national centre of excellence for joint 
replacements. It was approved as a national health registry in 2009, and in 2010 the 
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name of the national centre was changed to the Norwegian National Advisory Unit on 
Arthroplasty and Hip Fractures. 
The main purpose of the NAR has been to function as a surveillance tool to detect 
inferior results of implants as early as possible and to avoid poor performing implants 
from being used in large number of patients, leading to excess patient suffering and 
high cost for society. Data on a total hip replacement operation is reported to the 
registry by the operating surgeon, using a one-page standard form completed in the 
operation theatre, just after surgery. The form includes the patient’s unique national 
identification number, date of the operation, diagnosis, operated side, former surgery 
to that particular joint, operating technique, details and stickers/labels from the 
components used attached to the form, use of antibiotics and thrombosis prophylaxis 
and more (Appendix 7). Both primary operations and reoperations defined as 
removing or changing of prosthesis components are registered. Reoperations can be 
linked to their corresponding primary operation using the unique personal 
identification number. 
Reporting to NAR is not mandatory, but it has been estimated that at least 97% of 
joint replacements operated in Norway are reported (Espehaug et al. 2006), and 
completeness and coverage analyses show a rate of 96% reported to NAR during the 
years 2008-2012 (Helsedirektoratet 2014). NAR is licensed by the Data Inspectorate 
of Norway and patients give written informed consent to be included in the registry.  
Annually approximately 8,000 primary THRs are reported to NAR, and there are 
about 1,300 reoperations (Norwegian Arthroplasty Register 2014). 
The quality and revision rates for the prostheses have shown large variations 
(Espehaug et al. 2009, Hallan et al. 2010, Hallan et al. 2007, Havelin et al. 2000), in 
particular for the uncemented prostheses (Hailer et al. 2010, Havelin et al. 1994, 
Havelin et al. 1995). The quality of modern uncemented prostheses is better than for 
prostheses 10 to 20 years ago (Hallan et al. 2010, Hallan et al. 2007). However, 
surveillance of new products with respect to adverse outcomes is crucial, also in the 
future. 
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8.3 Linking of CRN and NAR 
Nationwide and internationally, research based on Norwegian health registries is of 
high scientific value and has proven to give new and crucial knowledge (Havelin et 
al. 2000, Moster et al. 2008, Vikse et al. 2008). Since Norway has the unique 
personal identification number for each inhabitant used in most registries, linkage of 
two or more registries is possible, when all applications for such research have been 
approved by the relevant health authorities. For a scientist with a desire to enrich the 
world with new knowledge, the road is however long and time-consuming to obtain 
the necessary approvals and the linkage of data. 
In 2005 Sophie D. Fosså contacted the NAR concerning a project proposal from the 
National Centre of Competence for Long-term Studies after Cancer. Many patients 
with gynaecological, urological and gastrointestinal cancer receive high-dose 
radiotherapy given to target volumes that include both or at least one hip. With the 
typical four-field box technique, each hip is irradiated with approximately 20-30 Gy, 
delivered to the skeletal and the soft tissue components. These radiotherapy doses 
may lead to reduced osteoblast activity lasting for many years (Fosså and Winderen 
1993), hence one may expect increased risk of skeletal damage and arthrosis in the 
irradiated hip (Fu et al. 1994).  
This proposal coincided with similar thoughts at the NAR. Orthopaedic surgeons and 
biostatisticians had the idea to study cancer as an alternative endpoint after THR as 
has been done by other national arthroplasty registries (Brewster et al. 2013, Goldacre 
et al. 2005, Makela et al. 2012, Makela et al. 2014, Nyren et al. 1995, Onega et al. 
2006, Paavolainen et al. 1999, Paavolainen et al. 2002, Smith et al. 2012, Visuri et al. 
1996, Visuri et al. 2003, Visuri et al. 2010, Visuri et al. 2006, Wagner et al. 2011). 
Since more young people now receive THR, the lifespan of THR patients has 
increased and long-term effects after prosthesis are important to investigate. Long-
term effects such as pulmonary embolisms (PE), deep venous thrombosis and death 
have been in focus, but concerns have been raised as to whether insertion of an 
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implant might lead to subsequent malignancies (Keel et al. 2001, Lidgren 2008, 
Mabilleau et al. 2008, Meyskens 2007).  
Based on the common idea of a linkage between the CRN and the NAR, a study 
group was established, the project was planned, and the necessary approvals were 
obtained (Appendices 1-4). 
In 2007 the linking between the NAR and the CRN was performed by the CRN. Files 
containing information on all cancer patients from 1953 to 2005 and all patients with 
THR from 1987 to 2006 were created. A total of 741,901 patients with either cancer 
diagnosis or THR was included, and of these 17,235 patients were registered in both 
registries.  
In 1998 the CRN started a national sub-register containing information about 
radiation therapy given to cancer patients. Since this information was crucial in the 
studies on long term effects after cancer treatment, we applied for data on radiation 
therapy on a subgroup of cancer patients in 2009. Information on radiation dosages 
given to the requested patients was obtained for the period 1998 to 2006. 
A new linkage between CRN and NAR was applied for in 2011. This was done to 
achieve longer follow-up and add more recent years to the study. Our new file 
included cancer cases and THRs up to 2009. The new linkage had a total of 867,735 
patients, of whom 23,515 were registered in both registries.  
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Figure 6: Data structure from linking CRN and NAR. See text under Papers 1-3 for 
explanation.  
All studies in this thesis are based on these linkages between NAR and CRN.  
Paper 1 
In Paper 1, all patients in CRN linked to NAR from the linking in 2007 
(#CRN1=669,432), were used. Patients with THR prior to cancer diagnosis were 
excluded from the analysis (N=8,672). We included patients aged from 16 to 90 years 
at the time of their first cancer diagnosis and the patients had to be alive per 
September 1st 1987 (the starting date for registration of THRs in the NAR). 
There were 403,809 patients fulfilling the inclusion criteria for the study.   
Paper 2 
In Paper 2 the sub-register of CRN was used to access information on radiation 
therapy for two patient groups. We defined an exposure group of women who had 
undergone pelvic curative external beam radiotherapy for gynaecological cancer and 
a non-exposure group of female breast cancer patients who had undergone curative 
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irradiation (40-60 Gy) to the chest area without routine high-dose radiotherapy to the 
pelvic region. 
All the radiation therapy was given between the years 1998 and 2006. Only patients 
who started radiotherapy within six months after diagnosis were included in the 
study. Furthermore, we restricted the inclusion to patients with target doses of 40-60 
Gy provided over at least 28 days. Patients who had received a THR prior to radiation 
therapy were excluded. 
Included in the study were 8,507 patients, 962 with pelvic radiation exposure and 
7,545 without pelvic radiation exposure. 
Paper 3 
In Paper 3 we used the linking from 2011, and all patients in the NAR were used as 
the target population (#NAR2=107,175). Cancer cases were considered outcomes 
(#N2=23,515). All THRs were inserted in the period from 1987 to 2009. Patients with 
cancer diagnosis prior to THR were excluded from the analysis (N=11,005). Only 
patients with known prosthesis fixations (cemented, uncemented, hybrid or reversed 
hybrid) were included in the study. 
A total of 90,586 patients with a first primary THR were included in the study. 
8.4 Outcome 
In Paper 1 and Paper 2 the main outcome was THR after a cancer diagnosis. Cancer 
patients were followed from the date they had been diagnosed with cancer and until 
the date of a THR, death, emigration or end of study, whichever came first. 
In contrast, being diagnosed with cancer after a THR was the outcome in Paper 3. 
THR patients were divided into groups by the prosthesis fixation technique and 
followed from primary operation until a cancer diagnosis, death, emigration or end of 
study, whichever came first. 
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In Paper 2 and Paper 3 death was considered a competing outcome in the statistical 
analyses. 
In Paper 1 the outcome was 8,563 out of 403,809 patients receiving a primary total 
hip replacement.  
In Paper 2, 26 out of 962 women with gynaecological cancer and 253 out of 7,545 
women with breast cancer received a THR after the date of primary diagnosis of 
cancer. 
For Paper 3 we observed 12,383 of 90,586 patients diagnosed with at least one cancer 
incident after a total hip replacement. 
8.5 Approvals, ethics and conflict of interest 
The linking of the Norwegian Arthroplasty Register and the Cancer Registry of 
Norway was approved by the Regional Committee for Medical and Health Research 
Ethics, Western Norway in 2006 (170.06). The project was also approved by the 
Norwegian Data Inspectorate (No. 14970). The Norwegian Directorate for Health and 
Social Affairs gave exemption from duty of confidentiality in 2006. The approvals 
are found in the appendices. 
All co-authors declared no conflict of interest. Both registries involved had 
governmental funding, and the data were treated in full confidentiality and within 
laws and regulations. 
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9. Statistical analyses 
The general statistical methods used in this thesis are event history analyses. When 
linking the Cancer Registry of Norway and the Norwegian Arthroplasty Register, we 
observe either time from cancer until a total hip replacement (THR) or time from a 
THR to cancer. Hence, the outcomes we study will in general be time from some 
initial event (either cancer or THR) to the outcome of interest (receiving a THR, 
being diagnosed with cancer, or death). Since not all individuals treated for cancer 
will receive a THR, and not all patients with a THR will get cancer, we have a 
mixture of the two outcomes time (t) and the outcome itself. In general we can define 
T as the minimum of two events C and Z, T=min(Z,C), where Z is time to observing 
an event and C is time to censoring.  
A censored observation can be the time when an individual emigrates, time of death 
(when time to cancer is the outcome of interest), or the maximum potential time of 
follow-up (completed years of registration at the time of linkage). 
9.1 Standardized incidence ratio (SIR) 
Standardized incidence ratios (SIR) and standardized mortality ratios (SMR) have 
been used in epidemiology for decades (Breslow and Day 1985, Breslow and Day 
1987). The general idea of the standardized ratios is to quantify the increased risk, for 
a disease or death, for a group of patients compared to the risk found in the general 
population. The numerator, O, in the calculation of the SIR (or SMR) is the total 
number of events observed for the patients, while the denominator, E*, is the number 
of events expected to be found in the general population, when gender, age and 
calendar year are taken into account.   
ܵܫܴ = ܱܧכ 
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9.2 Cox regression 
The Cox model was introduced in 1972 and it has been one of the most popular 
models in statistical analyses of event history data (Cox 1972).  
The risk set at a particular point in time consists of individuals (at point t) who are at 
risk for experiencing the event of interest. Individuals have entered the study and 
have survived up to time t. Individuals leave the risk set either when they experience 
the event, or when they are censored. 
The hazard rate h(t) has traditionally been important in regression models for survival 
data. The hazard can be interpreted as the instant probability of an event, within a 
short period of time after time t, given that the individual was at risk at time t: 
݄(ݐ) = limௗ௧՜଴
ܲ(ݐ ൑ ܶ < ݐ + ݀ݐ| ܶ ൒ ݐ)
݀ݐ  
Where T is a random variable of survival times, dt denotes a small interval of time 
and P is the conditional probability that the survival time of a subject is between t and 
t+dt, given that a subject has survived up to time t. 
In ordinary survival analysis, with one outcome, there is a one-to-one relation 
between the hazard and the survival function S(t). 
ܵ(ݐ) = ݁ି׬ ௛(௨)ௗ௨೟బ  
The survival function is the probability for not yet to have had an event. 
ܵ(ݐ) = ܲ(ܶ > ݐ) 
F(t) is the cumulative distribution function, the risk for experiencing an event before 
time t: 
ܨ(ݐ) = 1െ ܵ(ݐ) 
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At time zero no individuals will per definition have had an event (S(0)=1), while at 
time infinite all individuals will have experienced an event (S(f)=0).  
Hence, in single event survival analyses, the Cox proportional hazards regression 
model is central, since it also will be a regression model for S(t). The Cox model is 
semiparametric in that it has a nonparametric baseline function (h0(t)). The 
proportionality in the Cox model is crucial since covariates (X) and regression 
coefficients (ȕ) are assumed to have a constant influence on the exponential scale 
over time. 
݄௜(ݐ) = ݄଴(ݐ) ή ݁ఉ೅௑೔ 
9.3 Competing risk model 
When there is more than one outcome of interest, or there are important outcomes 
competing with the primary outcome of interest, methods from ordinary survival 
analyses may be inaccurate. For the competing risk model with death and receiving a 
total hip replacement as competing outcomes, two hazard rates have to be defined. 
 
Figure 7: A competing risk model showing time from cancer diagnosis to receiving a 
THR or death. 
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In this model there will be one hazard for each of the two arrows. Furthermore, it is 
easily seen that the survival function (which is the probability of being alive with 
cancer and no THR) is directly related to both outcomes. 
ܵ(ݐ) = 1െ (ܨଵ(ݐ) + ܨଶ(ݐ)) 
Calculating ordinary survival curves (e.g. using the Kaplan-Meier estimator) for each 
of the outcomes will therefore not give probabilities for each of the two outcomes. 
However, since the two outcomes are assumed to be mutually exclusive, the total 
hazard will be the sum of the two hazards for the two events. 
்݄(ݑ) = ݄ଵ(ݐ) + ݄ଶ(ݐ) 
The overall survival (the probability of being alive with cancer and no THR) can be 
calculated as the product of the “survival” curves for each of the two outcomes. 
ܵ(ݐ) = ݁ି׬ ௛೅(௨)ௗ௨೟బ = ݁ି׬ ௛భ(௨)ௗ௨೟బ ή ݁ି׬ ௛మ(௨)ௗ௨೟బ = ଵܵ(ݐ) ή ܵଶ(ݐ) 
The probability for either of the two outcomes is on the other hand 
ܨ௝(ݐ) = නܵ(ݑ) ή ௝݄(ݑ)݀ݑ
௧
଴
,  j = 1,2 
For competing risk models, the one-to-one relation between the hazard function and 
the survival function (and the cumulative density function F(t)) is no longer present. 
As an alternative, Fine and Gray proposed a regression model yielding a sub-hazard 
ratio (Fine and Gray 1999). The sub-hazard is defined as 
௝݄כ(ݐ) = log ቀ1െ ܨ௝(ݐ)ቁ 
The Fine and Gray regression model is defined using the sub-hazard, and the 
exponential of the coefficients in the model is interpreted as sub-hazard ratios. 
݄௜כ(ݐ) = ݄଴כ(ݐ) ή ݁ఉ೅௑೔ 
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9.4 Models with time-dependent variables 
Time-dependent variables can be implemented in both the Cox regression model and 
the Fine and Gray model. There are two types of variables used in this thesis. The 
first is a time-dependent indicator, which identifies changes in the effect of covariates 
before and after a defined time (e.g. 10 years as in Paper 3). If we for instance 
introduce two indicators I(Td10) and I(T>10), we are able to distinguish between the 
effect in the first 10 years and the last 10 years. 
In the Cox model this would look like 
݄௜(ݐ) = ݄଴(ݐ) ή ݁ఉభήூ೔(்ஸଵ଴)ାఉమήூ೔(்வଵ଴) 
The Fine and Gray model would be equal, but uses sub-hazards. 
Additionally, time dependent indicators, Xi(t), were used to identify individuals who 
have a change in a variable over time (e.g. a new operation or a new cancer case) 
which can change the risk for the outcome of interest. 
9.5 Statistical software 
In Paper 1 we used S-plus 7.0 for Windows and SPSS 15.0, in Paper 2 we used R 
version 3.0.0 and SPSS version 21.0, and in Paper 3 we used SPSS version 22.0, R 
version 3.0.2, Stata version 13-IC and a custom-made Fortran programme (Lie et al. 
1998). 
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10. Summary of Papers 
10.1 Paper 1 
Dybvik E, Furnes O, Fosså SD, Trovik C, Lie SA. Long-term risk of receiving a 
total hip replacement in cancer patients. Cancer Epidemiol. 2009 Oct;33(3-4):235-
41. 
Background and purpose: Approximately two thirds of cancer patients survive more 
than five years and we wanted to investigate whether these patients have an increased 
risk of receiving a total hip replacement compared to the general population in 
Norway. 
Patients and methods: The study was based on a linkage between the Cancer Registry 
of Norway and the Norwegian Arthroplasty Register. To be included, patients had to 
fulfil three criteria; age 16-90 years at the date of their first cancer diagnosis, no hip 
prosthesis prior to the first cancer diagnosis and alive per September 1st 1987. 
403,809 patients were included in the study, and 8,563 patients received a THR. The 
study ended on December 31st 2006.  We used standardized incidence ratios (SIRs) 
as a measure of THR among cancer patients divided into gender, age groups and 
groups of cancer locations.  
Results: Cancer patients had an overall increased risk of receiving a THR compared 
to the general population (SIR=1.15 (95% CI: 1.12-1.17)). When comparing to the 
general population, we found a statistically significant increased risk for some 
malignancies: malignant lymphoma (SIR=1.30 (95% CI: 1.15-1.46)), selected cancer 
types located within the pelvic region (SIR=1.20 (95% CI: 1.16-1.24)), leukaemia 
(SIR=1.17 (95% CI: 1.01-1.34)) and breast (SIR=1.13 (95% CI: 1.08-1.18)). 
Conclusions: In this study we found a statistically significant increased risk for 
receiving a total hip replacement for cancer patients, compared to the incidences of 
such prostheses in the Norwegian population.  
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10.2 Paper 2 
Dybvik E, Furnes O, Fosså SD, Trovik C, Lie SA. Pelvic irradiation does not 
increase the risk of hip replacement in patients with gynecological cancer. Acta 
Orthop. 2014 Dec; 85 (6): 652-6. 
Background and purpose: After five years, about 60% of cancer patients are still 
alive. These patients could develop adverse effects after the treatment they received. 
Irradiation to the pelvic region could e.g. cause bone damage and result in an 
increased risk of fracture or degeneration of the hip.  
Patients and methods: The study was based on a linkage between the Cancer Registry 
of Norway and the Norwegian Arthroplasty Register. From a sub-register of CRN, we 
obtained information on radiotherapy treatment. We identified an exposure group of 
962 women with curative radiotherapy for gynaecological cancer and a non-exposure 
group of 7,545 women with curative radiotherapy for breast cancer (but without 
pelvic irradiation). All patients were treated between 1998 and 2006; they received 
40-60 Gy for at least 28 days and radiation started within six months of diagnosis. We 
used Fine and Gray competing risk analysis to calculate sub-hazard ratios (SHR) and 
cumulative incidence functions (CIF) for receiving a THR, accounting for differences 
in mortality. 
Results: From the exposure group, 26 out of 962 patients (3%) with gynaecological 
cancer received a THR. 253 out of 7,545 (3%) breast cancer patients received a THR. 
The eight-year CIFs for receiving a THR were 2.7% (95% CI: 2.6-2.8) and 3.0% 
(95% CI: 2.95-3.03) for gynaecological cancer and breast cancer respectively. From 
competing risk models with death as a competing outcome the SIR was 0.80 (95% 
CI: 0.53-1.22, p=0.30).  
Conclusions: We found no statistically significantly higher risk for receiving a THR 
for patients with gynaecological cancer treated with pelvic radiotherapy compared to 
patients with breast cancer without pelvic radiotherapy. 
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10.3 Paper 3 
Dybvik E, Furnes O, Havelin LI, Fosså SD, Trovik C, Lie SA. Increased risk of 
cancer for uncemented total hip replacements. A study of 90,586 patients in the 
Norwegian Arthroplasty Register linked to the Cancer Registry of Norway. 
Submitted.   
Background and purpose: Concerns have been raised that implants could lead to a 
future increased cancer risk. Several different materials and metals are used in joint 
prosthesis, and different fixation techniques and types of articulation for the surface 
of the joint can lead to an increased escape of particles or ions into the human body. 
The first aim was to determine if THR patients had a higher cancer risk than the 
general population in Norway. The second aim was to see if there were differences 
between the types of fixations in the risk for late development of cancer in patients 
with a THR. 
Patients and methods: Based on patients reported to the Norwegian Hip Arthroplasty 
Register in the period from 1987 to 2009, we identified 90,586 patients with one 
primary total hip replacement (THR). These patients were linked to the Cancer 
Registry of Norway and we followed them until a cancer event, emigration, death or 
end of the study, whichever came first.  Standardized incidence ratios (SIRs) and 
survival curves compared the cancer risk for the patients with the general population. 
To account for selection mechanisms at time of primary operation we used Cox 
regression analyses and the Fine & Gray competing risk model with time-dependent 
covariates to compare the difference in cancer risk between different types of 
fixations after 10 years of follow-up adjusted for the difference in cancer risk in the 
first 10 years of follow-up. 
Results: When comparing to the general population, we found a negligibly increased 
risk for cancer for the THR patients after 10 years of follow-up (SIR= 1.08, 95 % CI: 
1.04-1.12). When comparing types of fixations, we found an increased relative risk 
for cancer for uncemented prostheses (SHR=1.77, 95 % CI: 1.57-2.00, p<0.001) and 
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for hybrid prostheses (SHR=1.77, 95 % CI: 1.47-2.17, p<0.001), compared to 
cemented prostheses. 
Conclusions: Total hip replacements consisting of at least one uncemented 
component seem to be followed by an increased risk for late development of cancer, 
compared to THRs where all components are cemented. 
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11. General discussion 
11.1 Methodological considerations 
11.1.1 Study designs 
In medical research it is desirable to reveal new information on health, diseases and 
treatments. There are in general two different types of analytical approaches: 
experimental studies and observational studies. In experimental studies the researcher 
has full control over the intervention given to all individuals, while in observational 
studies the researcher collects information on groups of interest, but has no influence 
over who receives which treatment (Altman 1991, Rothman and Greenland 1998, 
Röhrig et al. 2009).  
When specifying study design and sample size, it is essential to collaborate with an 
experienced biostatistician (Altman et al. 1983, Pripp 2013, Röhrig et al. 2009). The 
quality and reliability of studies could be improved if all important details are 
considered ahead of the study in collaboration between biostatisticians and clinicians.  
Studies can be classified as prospective or retrospective. In a prospective study 
exposure and covariates are recorded prior to the outcome occurrence and individuals 
are followed to the occurrence of the event of interest.  The outcome of interest 
should be common, since rare outcomes will be statistically challenging. A 
retrospective study looks backward in time and examines the relations between 
outcomes and preceding exposures (suspected risks or factors established at the start 
of the study). For retrospective studies confounders and bias are more common and 
problematic than in prospective studies.  
In a cohort study, the researcher defines two or more groups of disease-free people 
and compares them according to the extent of exposure to a potential cause of a 
disease, and then follows these to a disease experience. A case-control study explores 
cases with known exposure and compares these with a control group from a 
population to determine relative size of incidence rates of the disease. A cross-
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sectional study includes all persons in the population at one specific point in time, 
while in a longitudinal study individuals have repeated observations over periods in 
time. 
Clinical trials are experimental studies and should ideally be randomized, so that the 
treatment is allocated to patients at random. Blinding is a method to avoid bias in 
clinical trials and double blinded studies, where neither the patient nor the clinician 
knows who receives which treatment, are considered the gold standard. 
Randomized clinical trials (RCT) are considered to be on the highest level of 
evidence for finding causal relations between an exposure and an outcome (Figure 8) 
(Concato et al. 2000). Implementing a RCT to examine the effect of radiation therapy 
and the risk of prosthesis would not be possible, neither practically or ethically. To 
randomize types of treatment given to treat cancer is problematic, since every cancer 
case is unique. Studies of long-term effects after cancer treatment in which rare 
events are expected to develop after at least 10 years requires high numbers of 
patients. 
A randomized study to examine if brands or fixations of prosthesis increase the risk 
for developing cancer would be difficult. Studies of hip replacements generally 
require long follow-up and high numbers of patients since the quality of implants is 
generally good. Adverse events are rare and they develop over a long time with small 
differences between groups. Consequently, cancer as outcome requires long follow-
up and large groups of patients. 
Concerns have been raised that observational studies find stronger treatment effects 
than RCTs. Two studies (Benson and Hartz 2000, Concato et al. 2000) have searched 
databases for published studies on treatments for the same conditions in RCTs and 
observational studies and both studies conclude that RCTs and well-designed 
observational studies give comparable results. A Cochrane Review from 2014 had 
very similar results (Anglemyer et al. 2014). 
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Figure 8: Grades of evidence for the purported quality of study design (Concato et 
al. 2000).  
For our project, an RCT was not a feasible study design, and all studies in this thesis 
are therefore observational studies with a prospective cohort design. 
11.1.2 Completeness and quality of data 
Register studies have limitations in methodology and quality. Completeness and 
quality of data are amongst other things essential to draw correct conclusions. The 
CRN has high completeness with 99% coverage of all cancer cases in Norway 
(Cancer Registry of Norway 2015, Larsen et al. 2009). A study has shown that NAR 
contains records for 97% of all primary THRs in Norway (Espehaug et al. 2006) and 
a coverage analysis of primary operations and revisions gave a completeness of 94-
95%. This rate was higher if only primary operations were considered 
(Helsedirektoratet 2014). Quality of data depends on several factors; mistakes can be 
made by the reporting physician (or other health care workers) or by the technical 
staff at the registries. Poor design of the registration forms could also lead to incorrect 
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reporting. The quality of registration has been validated and found reasonably 
accurate both in CRN (Larsen et al. 2009) and in NAR (Arthursson et al. 2005, 
Engesaeter et al. 2011, Hulleberg et al. 2008, Lehmann et al. 2012). With all available 
data on completeness and coverage, we consider the data of the registers used in this 
thesis to be of good quality. 
The Norwegian population is a relatively stable population where emigration rates 
have been minor (Statistics Norway 2015). The entire population is traced by the 
national registries and statuses of immigration, emigration or death are also recorded 
accurately. 
11.1.3 Outcome measures 
In the CRN, researchers have studied long-term effects after cancer in numerous 
outcomes, e.g. hormonal dysfunction after radiotherapy to the head and neck region 
(Seland et al. 2015), long-term income in colorectal cancer patients (Hauglann et al. 
2014), increased stomach cancer risk after radiotherapy for testicular cancer 
(Hauptmann et al. 2015) and arm and shoulder morbidity following surgery and 
radiotherapy for breast cancer (Johansen et al. 2014). Using THR as an outcome after 
cancer diagnosis has never been attempted in the Norwegian population before. 
There could hypothetically be a selection bias in our studies, since THR is a treatment 
generally given to healthier patients (Lie et al. 2000). A cancer patient could have a 
painful and worn out hip, but the indication for a THR results from a balance between 
the severity of the hip disease and the general health of the patient. General health, 
comorbidity and mortality for different cancer types vary, and patients may be 
selected to receive a THR based on these factors. 
A hip fracture could be a more sensitive measure of a diseased hip (Gjertsen et al. 
2008), since there is not a selection of patients treated for hip fractures similar to the 
selection for receiving a THR. In Norway the incidence of hip fractures is among the 
highest in the world (Cooper et al. 2011, Kaastad et al. 1998). The reasons for the 
high number of hip fractures in Norway have not been completely investigated. 
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However, lifestyle factors such as exercise, smoking, alcohol consumption and diet 
could be a reason (Pripp and Dahl 2015), and the use of medications may be another 
explanation (Bakken et al. 2013, Bakken et al. 2014).  
Other alternative outcomes could be patient-reported measure of hip pain 
(Waldenstrom et al. 2012) or radiographic examination of all patients to disclose joint 
diseases. 
Time from primary operation until failure of the implant is generally used as the 
primary outcome in the majority of THR studies from NAR. In Paper 3 we used time 
until a cancer diagnosis as outcome after THR. In recent years, increased numbers of 
both younger people and elderly people with good general health have received a 
THR. This increase may be due to an increasingly elderly population, better 
anaesthetics, lower risk associated with the operation and better quality of the 
prosthesis. Concerns have been raised as to whether insertion of metal prosthesis 
could lead to an increased risk for late development of cancer. Hence, cancer 
diagnosis from the CRN is a well-defined outcome measure after THR. 
11.1.4 Validity 
In scientific research, validity is to what extent a study is able to answer the questions 
it is intended to answer. In Modern Epidemiology (Rothman and Greenland 1998) 
validity is separated into two components: internal validity and external validity 
(Figure 9). 
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Figure 9: Validity according to Rothman and Greenland. 
Internal Validity 
Internal validity implies whether the conclusion is valid for the population in the 
study. Internal validity is a precondition for external validity. Systematic errors can 
violate the internal validity. Systematic errors can be separated into three types: 
selection bias, information bias and confounding. 
Selection bias occurs if the sample is not representative for the study population from 
which it is selected. Possible causes of selection bias are individuals refusing to 
participate at the start of the study or dropouts during follow-up. NAR is based on 
written consent from all patients, and therefore it is possible to refuse to be registered 
there from the start. Furthermore, individuals could be lost to follow-up, e.g. due to 
emigration. The CRN is a mandatory register and selection bias is in general not a 
problem. All studies in this thesis are based on data from CRN and NAR. Both 
registries have demonstrated very high completeness. The data used in the present 
thesis can therefore be considered population-based. 
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Information bias occurs if information on exposure or disease is incorrectly 
registered. For the CRN all cancers and suspected cancers are reported. The precision 
of the cancer diagnosis is high, since it is often verified by biopsies. The accuracy for 
the insertion of a THR is very precise, since the information on this is registered at 
the operating theatre by the surgeon.    
Confounding implies that the effect of the exposure of interest becomes mixed with 
the effect of other variables (Rothman and Greenland 1998). The confounding 
variable must be associated with both the exposure and the outcome. 
Confounding could be common causes, e.g. lifestyle factors related to the risk for 
cancer and the risk for a damaged hip joint subsequently needing a THR.  
External validity 
External validity is the ability to generalize results and conclusions from the study 
population to individuals outside that population (Rothman and Greenland 1998). 
Internal validity is a prerequisite for external validity. 
External validity may be problematic in experimental studies on rare subgroups of 
patients. For population-based observational studies, external validity is generally not 
the main problem, since it is the population in large which is studied.  
Precision 
The absence of random errors is referred to as precision (Rothman and Greenland 
1998). Studies with large samples ensure high precision. In this thesis the populations 
are retrieved from reliable national registries leading to high precision of the 
estimates achieved. However, the number of cancer cases, especially in the exposure 
group in Paper 2, was relatively small. In order to increase the sample size of cancer 
individuals, collaboration with similar registries in other Nordic countries could be an 
option. 
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11.1.5 Statistical Methods 
Choice of statistical methods depends on the available data and the purpose of the 
study. 
Standardized incidence ratios (Breslow and Day 1985, Breslow and Day 1987) were 
used in Paper 1 and Paper 3. This method was used to describe the occurrence of 
THR in relation to time among cancer patients in Paper 1 and prevalence of cancer in 
patients with hip replacement in Paper 3 compared to the general population in 
Norway. Results obtained from SIR are easy to understand and can readily be 
compared to results from other settings. 
Survival analysis, or time to an event analysis (e.g. time until death, revision of 
prosthesis or time until cancer), is widely used in analysis of registry data. This 
analytical method takes into account that not all events of interest may have occurred 
before the end of the whole study or before the individual patient’s follow-up 
prematurely terminates, e.g. due to death or emigration. The most commonly used 
survival methods are Kaplan-Meier survival curves and Cox proportional hazards 
models. 
The Kaplan-Meier method (Kaplan and Meier 1958) is the most common method for 
estimation of survival probability. According to the Web of Science citation database 
(Web of Science 2015) this method has been cited in 39,473 published studies. The 
method has been rated as one of the most frequently cited statistics papers (Ryan and 
Woodall 2005), and placed as number 11 in the top 100 papers of most-cited research 
of all time (Van Noorden et al. 2014). The Kaplan-Meier method has been widely 
used in cancer research and in research on hip replacements. This method estimates a 
survival curve indicating the proportion of subjects who have not yet experienced the 
event of interest at various time points.  
The Cox proportional hazards (PH) model (Cox 1972) also plays an important role in 
analysing survival data. This method has been cited in 29,217 published studies and 
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is the second most cited statistical paper, ranked as number 29 in the top 100 papers 
(Van Noorden et al. 2014). 
A Cox regression model analyses the instantaneous rate of occurrence of an event, 
conditional on the event having not yet occurred. The Cox PH model hence enables 
estimation of the effect of covariates on the hazard rate. A crucial assumption of the 
model is that hazard ratio is constant over time, hence the term proportional hazards. 
The simplest test for proportionality is a plot of the log minus log of the survival 
curves. 
In survival analysis where the outcome is time to a single event, there is a one-to-one 
relation between the hazard rate and the survival function, and estimates from the 
Cox model can be used to directly estimate the effect of covariates on the survival 
probabilities. 
In recent years, models for competing risks have gained popularity. These models 
take into account that there could be several outcomes. The occurrence of the event of 
interest may be precluded by another event. The method for competing risks 
scenarios models the direct effect of covariates on survival probabilities for the event 
of interest. In Paper 2, the risk of receiving a THR competes with the risk of death, 
and similarly in Paper 3, the risk of developing cancer competes with the risk of 
death. Implementation of Fine and Grey competing risk models (Fine and Gray 1999) 
in commercial statistical packages (e.g. Stata and R) has accelerated the popularity of 
this method. The paper has been cited in 2,037 published studies. There is an 
alternative method for analysing competing risks (Klein and Andersen 2005), but this 
method has not been nearly as popular as the Fine and Gray method. 
Ignoring competing risks, or in ordinary survival probabilities treating competing 
events as a censored observation, would result in underestimation of survival 
probabilities for the event of interest. 
One challenge in event history analyses is that elements may change over time. Effect 
can change over time and patients can change characteristics over time. In both the 
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Cox and Fine and Gray model, this can be handled by including time-dependent 
covariates. This was used in both Paper 2 and Paper 3. 
11.2 Results 
11.2.1 Paper 1 
When comparing cancer patients to the Norwegian population in Paper 1, we found a 
small though statistically significant increase in the risk for receiving a total hip 
replacement for the cancer patients (SIR=1.15, 95% CI: 1.12-1.17). The results were 
consistent also when stratified by different anatomical sites of the cancers. 
Surprisingly, we did not find the highest risk for cancer located to the pelvic area. 
The highest risk was for lymphoma (SIR = 1.30, 95% CI: 1.15-1.46), followed by 
cancer in the pelvic area (SIR=1.20, 95% CI: 1.16-1.24), leukaemia (SIR=1.17, 95% 
CI: 1.01-1.34) and breast cancer (SIR=1.13, 95% CI: 1.08-1.18). The localization 
‘shoulders to diaphragm, without breast’ had a statistically significantly lower risk for 
THR (SIR=0.69, 95% CI: 0.57-0.81). The categorization of cancer locations we used 
in this study was based on the distance from the hip. 
Cox regression analysis showed that women with cancer had a significantly lower 
relative incidence of THR than men with cancer. When comparing cancer locations, 
cancer above the shoulders was set as the reference location. All locations with 
cancer diagnosed in 1990 or later had a higher relative incidence of THR than the 
reference location. 
Patients with malignancies may often be treated with hemi-arthroplasties, since this is 
considered to be a less complicated procedure in patients with comorbidities and 
limited life expectancy. Hence, our endpoint of THR may not be ideal.  
Furthermore, the most advanced cancer cases may have an increased risk for hip 
damage, but they also have the highest mortality rates. Concerning these 
malignancies, physicians may be reluctant to refer cancer patients to THR for some 
period of time due to their elevated risk of postoperative complications or expected 
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early death. We suspect therefore that the risk of damage to the hip joint might be 
higher than the observed risk for THR.  
Paper 1 did not include information on radiation therapy. The group of pelvic cancers 
included diagnosis with other treatments than radiation therapy. In early years, 
surgical treatment alone has been used in many gynaecological cancers and cancer in 
the rectum or urinary bladder. 
Survivors after malignant lymphoma and leukaemia had the highest risk of receiving 
THR. These two cancer types are treated with high doses of corticosteroids, in the 
case of leukaemia during long periods, often during childhood. It is known that 
corticosteroids decrease osteoblast activity (van der Sluis and van den Heuvel-Eibrink 
2008) and thus bone structure modelling, which is consistent with our observation of 
increased risk of caput necrosis. 
Increases in risk for THR found in Paper 1 could be related to treatment following 
cancer diagnosis. However, there may also be common causes explaining the cancer 
risk and the risk of receiving a THR. Life style factors related to the risk for cancer 
also relate to the risk for a damaged hip joint and subsequent need for a THR (Apold 
et al. 2011, Flugsrud et al. 2002, Parkin et al. 2011). Such factors may be obesity, 
smoking, alcohol abuse, occupation or genetic factors. 
The increased SIR for breast cancer could indicate a higher risk for THR, or there 
could be a common cause increasing both the risk for breast cancer and the risk for 
THR. A common cause could be age at which menopause occurs, since menopause 
may be related to the risk for breast cancer (Grodstein et al. 1997) and could also be 
related to bone mineral density and fractures (Zhang et al. 1997). A study by Shapiro 
and colleagues found a significantly increased risk for fracture of the femoral neck 
after breast cancer (Shapiro et al. 2001). 
We have not found any other population-based studies on the risk for receiving THR 
in cancer survivors. A Danish study on fracture risk in men after prostate cancer 
concluded with an increased risk for fracture at all ages, but most strikingly in men 
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aged 50-65. This increase was attributed to androgen deprivation therapy 
(Abrahamsen et al. 2007). A study from the US concluded an increased risk for pelvic 
or hip fractures in older women following pelvic irradiation (Baxter et al. 2005). 
11.2.2 Paper 2 
In Paper 2 we compared a group exposed to pelvic irradiation to a group without 
exposure to pelvic irradiation. The exposed group of gynaecological cancer was 
compared to the unexposed group of breast cancer. We did not find any statistically 
significantly higher risk for receiving total hip replacement in the exposure group 
compared to the unexposed group. 
Radiation treatment was given during the period 1998 and 2006, our follow-up 
extended to the end of 2010. From studies of second cancer related to anti-neoplastic 
treatment, it is known that the latency from the first to the subsequent malignant 
tumour is 10 years or more (Solheim et al. 2014, Travis et al. 2005), so our study may 
have too short follow-up to reveal differences.  
Even though Paper 2 was based on two large national registries, the number of 
available patients in the exposure group of gynaecological cancer with pelvic 
irradiation was limited. Our study included 962 patients, and only 26 (3%) of them 
received a THR.  
The mortality in our two groups was different. There were 305 deaths in the group of 
gynaecological cancer patients (32%), while there were 1,052 deaths in the group of 
breast cancer patients (14%).  For clinical outcomes like THR, death may be a 
substantial competing outcome that should be taken into consideration in the analysis, 
particularly for such elderly patients (Gillam et al. 2010, Gillam et al. 2011). We used 
the Fine and Gray method (Fine and Gray 1999) adjusted for death as a competing 
endpoint and THR as the endpoint of interest and breast cancer patients as the 
reference category, giving a sub-hazard ratio of 0.80 (95% CI: 0.53-1.22, p=0.30) for 
gynaecological cancer patients receiving a total hip replacement.  
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A THR is a clear-cut endpoint, but may not be ideal since the indication for a hip 
replacement results from a balance between the severity of the symptoms from the 
diseased hip and the general health of the patient. A total hip replacement is a major 
operation that is generally reserved for healthier patients (Lie et al. 2000). Patients 
could have diseased hips without receiving THR; these patients would thus not be 
included in the study. If gynaecological cancer patients have more severe comorbidity 
and higher mortality than breast cancer patients, this could lead to bias related to 
receiving a THR for the two cancer types.  
Østgård and colleagues recently published a study on comorbidity in acute myeloid 
leukaemia patients. Data from the Danish National Registry of Patients on all hospital 
admissions and hospital outpatient visits and a modified Charlson’s Comorbidity 
Index were used to categorize comorbidity (Ostgard et al. 2015). This method for 
categorizing comorbidity could be implemented in the Norwegian population and we 
could then find different groups of pelvic irradiation exposure with comparable 
comorbidity. 
11.2.3 Paper 3 
When using standardized incidence ratio (SIR), we found no overall increased risk 
for cancer after THR compared to the general population (SIR=0.96, 95% CI: 0.94-
0.97), while we found a small increase among 10-year survivors (SIR=1.08, 95% CI: 
1.04-1.12). When stratifying on fixations, the only increased risk was for uncemented 
THR after 10 years (SIR=1.58, 95% CI: 1.43-1.73).  
Several studies have been published from other national arthroplasty registries using 
SIR to compare cancer risk in THR or total knee replacements (TKR) with the 
general population (Brewster et al. 2013, Goldacre et al. 2005, Makela et al. 2012, 
Makela et al. 2014, Nyren et al. 1995, Onega et al. 2006, Paavolainen et al. 1999, 
Paavolainen et al. 2002, Smith et al. 2012, Visuri et al. 1996, Visuri et al. 2003, 
Visuri et al. 2010, Visuri et al. 2006). These studies conclude that there is no (or a 
negligible) increased risk of cancer after insertion of joint replacements, while 
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Wagner and colleagues report an increased risk of cancer after insertion of TKR 
(Wagner et al. 2011). 
SIR is the common analytical approach to compare observed cancer risk for THR 
patients with cancer rates in the general population. The method assumes that 
prosthesis patients are comparable to the general population. Lie and colleagues (Lie 
et al. 2000) have showed that THR patients overall have a reduced mortality 
compared to the general population. THR patients younger than 60 years have an 
increased mortality and patients older than 80 years have considerably reduced 
mortality compared to the general population. Furnes and colleagues have shown that 
young patients have predominantly received uncemented prosthesis while elderly 
patients have received cemented prosthesis (Furnes et al. 2001). Hence, due to 
selections of patients, the main analyses in Paper 3 do not use the general population 
as a reference. 
From studies on second cancer related to anti-neoplastic treatment, it is known that 
the latency period from the first to subsequent malignant tumour is 10 years or more 
(Solheim et al. 2014, Travis et al. 2005). 
Since the SIR generally underestimates the risk of cancer (Kirkeleit et al. 2013), we 
used the Fine and Gray competing risk method for comparing patients with more than 
10 years of follow-up and death as a competing event. We found an increased risk for 
being diagnosed with cancer for patients with uncemented THR (SHR=1.16, 95% CI: 
1.02-1.31, p=0.021) compared to cemented THR. 
To compare the different types of fixations for THR, we used the baseline cancer risk 
before 10 years as a reference. Using a competing risk model with cemented 
prosthesis as a reference and death as a competing outcome, both uncemented and 
hybrid prostheses had an increased cancer risk (SHR=1.77, 95% CI 1.57-2.00, 
p<0.001 and SHR=1.77, 95% CI: 1.47-2.17, p<0.001 respectively). We found 
increased cancer risk for patients with revision surgery (SHR=1.24, 95% CI: 1.15-
1.33, p<0.001) and patients with contralateral primary prosthesis (SHR=1.15, 95% 
CI: 1.09-1.20, p<0.001).  
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One, though unlikely, interpretation could be that cemented prostheses reduce the risk 
for cancer. A change in life style and activity could hypothetically lead to this. 
Uncemented prostheses, often made of titanium, have a large surface. In animal 
studies an increased amount of metal ions have been found in lungs, regional lymph 
nodes, blood and tissues close to the implant (Frisken et al. 2002, Woodman et al. 
1984). Direct contact between the uncemented prosthesis and tissue could lead to 
escape of ions. The structure of the surface of an uncemented prosthesis enables 
broad contact between the prosthesis and the bone, as the bone is intended to grow 
directly on the surface of the prosthesis. Furthermore, loosening of the prosthesis may 
induce increased debris from the prosthesis (Grosse et al. 2014). 
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12. Conclusions 
Compared to the general population, patients diagnosed with cancer have an 
increased risk to receive THR (SIR=1.15, 95% CI: 1.12-1.17). However, it remains 
uncertain whether this increase is due to the cancer and its treatment or due to other 
underlying factors. For selected malignancies treatment may play a major role, as in 
the iatrogenic modification of a breast cancer patient’s hormonal situation or high-
dose pelvic radiotherapy in patients with a cancer within the pelvis region.  
Overall there is no increased risk for cancer after THR compared to the general 
population. Only patients with an uncemented THR with more than 10-year follow-
up had a greater cancer risk than the general population. Additionally, we found an 
increased risk for developing cancer 10 years after receiving THR if one or more 
components were uncemented, compared to prostheses where both components were 
cemented. 
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13. Implications and future research 
The quality of cancer treatment is steadily increasing; many people survive cancer 
and stay alive for many years after the cancer diagnosis. In Paper 1 we found an 
increased risk for receiving THR for cancer patients. Therefore it is still crucial to use 
registries for surveillance of long term effects after cancer and cancer treatment. 
New designs and materials of prostheses are continuously being developed and 
introduced on the market. The clinical documentation for implants is not as strict as 
for medication. Therefore, health registries, such as the NAR, are needed for 
surveillance of implants nationwide both for short and long-term effects.  
 
Future research: 
x Long-term effects after cancer, using hip fracture as the outcome, would be a 
natural extension of the present studies. Combined with information on type 
and doses of treatment, this would strengthen the study. 
x An exposed group of pelvic irradiation could be compared to an unexposed 
group, but such a study needs to find a better group for the comparison, 
preferably including comorbidity data. A longer follow-up would also 
strengthen such a study. 
x There has been increased attention to the cancer risk for different THR 
articulations. A linkage between the NAR and the CRN will have increasing 
value in the years to come.  
x Co-operation with arthroplasty registries from the other Nordic countries 
should be initiated to enable analyses in truly large cohorts. 
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6\NGRPPHQVORNDOLVDVMRQGHEXWRUJDQ)RUQRQVROLGHVYXOVWHUPHGEHJUHQVHWXWEUHGHOVHSnGLDJQRVHWLGVSXQNWHWNDQGHWY UH
PXOLJnDQJLLKYLONHWRUJDQHOOHUKYLONHQUHJLRQV\NGRPPHQKDGGHVLWWXWVSULQJIHNVQRQ+RGJNLQO\PIRPLPDJHVHNNHOOHU
KRGJNLQO\PIRPPHGDIIHNVMRQEDUHDYO\PIHNQXWHUSnKDOVHQ
%DVLVIRUNUHIWGLDJQRVHQ
'HGLDJQRVWLVNHSURVHG\UHUVRPGDQQHUJUXQQODJHWIRUGLDJQRVHQDYNU\VVHV)RUXQGHUV¡NHOVHUXWI¡UWLSDWRORJLODERUDWRULXP
DQI¡UHVUHPLVVHQXPPHURJnUVDPWODERUDWRULXPDQVYDUOLJIRUXQGHUV¡NHOVHQ
9HLOHGQLQJWLOXWI\OOLQJDYVNMHPDHW
+RYHGJUXSSH
%HQPDUJVELRSVL
)¡GVHOVQXPPHU
7726538626
TIDLIGERE OPERASJON I AKTUELLE HOFTE (ev. flere kryss)
0 Nei
1 Osteosyntese for fraktur i prox. femurende 
2 Hemiprotese pga. fraktur
3 Osteotomi
4 Artrodese
5 Totalprotese(r)
6 Annen operasjon …………………………………………………....................
OPERASJONSDATO (dd.mm.åå) 
AKTUELLE OPERASJON (ett kryss)
1 Primæroperasjon (også hvis hemiprotese tidligere)
2 Reoperasjon (totalprotese tidligere)
3 Primær hemiprotese for annen indikasjon enn fraktur/fraktursekvele
AKTUELLE SIDE (ett kryss) (Bilateral opr.= 2 skjema)
1 Høyre          2 Venstre
ÅRSAK TIL AKTUELLE OPERASJON (KRYSS AV ENTEN I A ELLER B)
A Primæroperasjon pga. (evt. flere kryss)
1 Idiopatisk coxartrose
2 Rheumatoid artritt
3 Sekvele etter frakt. colli. fem.
4 Sekv. dysplasi
5 Sekv. dysplasi med total luksasjon
6 Sekv. Perthes
7 Sekv. Epifysiolyse
8 Mb. Bechterew
9 Akutt fraktura colli femoris
    Annet  ……….......….....…………………………………………………….........
(f.eks caputnekrose, tidl. artrodese o.l)
B Årsak til reoperasjon (evt. flere kryss)
1 Løs acetabularkomponent 10  Implantatfraktur femurdel
2 Løs femurkomponent 11  Implantatfraktur caput
3 Luksasjon 12  Implantatfraktur kopp
4 Dyp infeksjon 13  Implantatfraktur liner
5 Fraktur (i acetabulum) 14  Implantatfraktur annet: ............
6 Fraktur (av femur)   ..................................................
7 Smerter
8 Osteolyse i acetab. uten løsning   
9   Osteolyse i femur uten løsning
    Annet  ………………….......………………....………………………..…..........
(f.eks Girdlestonesituasjon etter tidl. infisert protese)
REOPERASJONSTYPE (ev. flere kryss)
1 Bytte av femurkomponent
2 Bytte av acetabularkomponent
3 Bytte av hele protesen
4   Fjernet protese og satt inn sementspacer
5   Fjernet sementspacer og satt inn ny protese
6 Fjernet protese (Girdlestone eller fjerning av sementspacer)
Angi hvilke deler som ble fjernet …………....…………………………...........
7 Bytte av plastforing
8 Bytte av caput
9 Bløtdelsdebridement for infisert protese
Andre operasjoner …………………………………………….………..............
TILGANG (ett kryss)
1 Fremre (Mellom sartorius og tensor) 3 Direkte lateral (Transgluteal)
2 Anterolateral (Mellom glut. medius og tensor)  4 Bakre (Bak gluteus medius)
5 Annen  ……………………………………………………………………..........
MINIINVASIV KIRURGI (MIS) 0 Nei       1 Ja
LEIE 0 Sideleie 1 Rygg
TROKANTEROSTEOTOMI 0 Nei 1 Ja
BENTRANSPLANTASJON (ev. flere kryss)
Acetabulum 0 Nei      1 Ja      2 Benpakking
Femur 0 Nei      1 Ja      2 Benpakking a.m. Ling/Gie
BENTAP VED REVISJON (Paprosky’s klassifikasjon se baksiden)
Acetabulum     1 I     2 IIA 3 IIB 4 IIC     5 IIIA 6 IIIB 
Femur 1 I      2 II 3 IIIA 4 IIIB    5 IV
PROTESEKOMPONENTER 
(Bruk klistrelapp på baksiden, eller spesifiser nøyaktig)
Acetabulum 
Navn/Type ……..............……………………………………………………………….............
ev. katalognummer ………........…………………………………………………...........
  Med hydroksylapatitt Uten hydroksylapatitt
1 Sement med antibiotika – Navn ………………………………………..................
2 Sement uten antibiotika – Navn ………………………………………..................
3 Usementert
Femur 
Navn/Type …………………………………………………………………….............
ev. katalognummer …………………………………………………………...........
  Med hydroksylapatitt Uten hydroksylapatitt
1 Sement med antibiotika – Navn ………………………………………..................
2 Sement uten antibiotika – Navn ………………………………………..................
3 Usementert
4 Resurfacing
Caput  
1 Fastsittende caput
2 Separat caput - Navn/Type ……………………………………………..................
ev. katalognummer …………………………………………………………............
Diameter ………………
SYSTEMISK ANTIBIOTIKA
0 Nei       1 Ja: 1 Profylakse 2 Behandling
Navn Dosering     Varighet i timer (døgn)
Medikament 1 ..........................................……..….....…...............….   ......timer (......døgn)
Medikament 2 ..........................................………..…..…...................   ......timer (......døgn)
Medikament 3 .................................................................……..……..   ......timer (......døgn)
TROMBOSEPROFYLAKSE  
0 Nei      1 Ja:  Første dose  1 Preoperativt     2 Postoperativt  
Medikament 1  ............................. Dosering opr.dag…………………………………….....
Dosering videre ………..........…  Varighet …… døgn 
Medikament 2  ............................. Dosering ………….....................  Varighet …… døgn 
Fast antikoagulasjon
0 Nei      1 Ja, type ..........................................................................................................
FIBRINOLYSEHEMMER
0 Nei      1 Ja, medikament: …………………………………….. Dosering ……………......
OPERASJONSSTUE
1 ”Green house”
2 Operasjonsstue med laminær luftstrøm
3 Vanlig operasjonsstue
OPERASJONSTID (hud til hud) …………………………min
PEROPERATIV KOMPLIKASJON
0 Nei   
1 Ja, hvilke(n) ............................................................................................................
ASA KLASSE (se baksiden for definisjon)
1 Frisk 
2 Asymptomatisk tilstand som gir økt risiko
3 Symptomatisk sykdom
4 Livstruende sykdom
5 Moribund
HOFTEPROTESER
ALLE TOTALPROTESER I HOFTELEDD REGISTRERES. Innsetting, skifting og fjerning av totalproteser i hofteledd, samt 
kantplastikk, bløtdelsrevisjon for infisert protese og hemiproteser på annen indikasjon enn fraktur/fraktursekvele. 
Hemiprotese for fraktur/fraktursekvele registreres på Hoftebruddskjema.
Nasjonalt Register for Leddproteser
Ortopedisk klinikk, Helse Bergen HF
Haukeland universitetssjukehus
Møllendalsbakken 11, 5021 BERGEN
Tlf  55973742/55973743
F.nr. (11 sifre).....................................................................
Navn:..................................................................................
(Skriv tydelig ev. pasient klistrelapp – spesifiser sykehus.)
Sykehus:............................................................................
Lege ................................................................................................... 
Legen som har fylt ut skjemaet (navnet registreres ikke i databasen).
5(77/('1,1*7,/+2)7(3527(6(5
5HJLVWUHULQJHQJMHOGHULQQVHWWLQJVNLIWLQJRJIMHUQLQJDYWRWDOSURWHVHULKRIWHOHGGVDPWNDQWSODVWLNNEO¡WGHOVUHYLVMRQIRULQILVHUWSURWHVHRJKHPLSURWHVHUSnDQQHQLQGLNDVMRQHQQ
IUDNWXUIUDNWXUVHNYHOH+HPLSURWHVHIRUIUDNWXUIUDNWXUVHNYHOHUHJLVWUHUHVSn+RIWHEUXGGVNMHPD(WWVNMHPDI\OOHVXWIRUKYHURSHUDVMRQ)¡GVHOVQXPPHUVLIUHRJV\NHKXVQDYQPnSnI¡UHV
$NWXHOOHUXWHUPDUNHUHVPHGNU\VV3nHJHW6DPW\NNHVNMHPDVNDOSDVLHQWHQJLVDPW\NNHWLOUDSSRUWHULQJWLO/HGGUHJLVWHUHW6DPW\NNHVNMHPDVNDOODJUHVLSDVLHQWMRXUQDO
$.78(//(23(5$6-21
3ULP URSHUDVMRQHU'HWWHHUI¡UVWHWRWDOSURWHVHRSHUDVMRQ
5HRSHUDVMRQWRWDOSURWHVHWLGOLJHUH)MHUQLQJDYSURWHVHGHOHUIHNV*LUGOHVWRQHPnUHJLVWUHUHV.DQWSODVWLNNIHNV3/$'RJEO¡WGHOVUHYLVMRQHUIRULQIHNVMRQ
UHJLVWUHUHVVHOYRPSURWHVHGHOHULNNHVNLIWHV
3ULP UKHPLSURWHVHIRUDQQHQLQGLNDVMRQHQQIUDNWXUIUDNWXUVHNYHOH+HPLSURWHVHIRUIUDNWXUIUDNWXUVHNYHOHUHJLVWUHUHVSn+RIWHEUXGGVNMHPD
c56$.7,/$.78(//(23(5$6-21
.U\VVDYXQGHU$YHGSULP URSHUDVMRQHURJXQGHU%YHGUHRSHUDVMRQHU,%PnGXNU\VVHDYIRUDOOHnUVDNHQHWLOUHRSHUDVMRQHOOHUIRUNODUHPHGIULWHNVW
5(23(5$6-2167<3(
)MHUQLQJDYSURWHVHGHOHUIHNV*LUGOHVWRQHPnUHJLVWUHUHV.DQWSODVWLNNIHNV3/$'RJEO¡WGHOVUHYLVMRQHUIRULQIHNVMRQUHJLVWUHUHVVHOYRPSURWHVHGHOHULNNHVNLIWHV
7,/*$1*
'HWYLVHVWLODUWLNNHO5HLJVWDG$%ORP+DJHQ76QLWWI¡ULQJYHGWRWDOSODVWLNNLKRIWHOHGGHW7LGVVNU1RU/DHJHIRUHQ0DU
%(175$163/$17$6-21%HQSURSSVRPVHPHQWVWRSSHUUHJQHVLNNHVRPEHQWUDQVSODQWDW
3527(6(.20321(17(5$FHWDEXOXP)HPXU&DSXW7URNDQWHUGHORJKDOVKYLVGLVVHHUVHSDUDWHGHOHU
%UXNKHOVWNOLVWUHODSSHQHVRPI¡OJHUPHGSURWHVHQ/LPGLVVHSnEDNVLGHQDYVNMHPD$OWHUQDWLYWVNULYLQQSURWHVHQDYQNDWDORJQXPPHUHOOHUSURWHVHQDYQVW¡UUHOVH
PDWHULDOHRYHUIODWHEHOHJJRJGHVLJQ6HPHQWQDYQPnDQI¡UHV
.203/,.$6-21(52JVnRSHUDVMRQHUKYRUSDVLHQWHUG¡USnRSHUDVMRQVERUGHWHOOHUUHWWHWWHURSHUDVMRQVNDOPHOGHV9HGVWRUVWRUEO¡GQLQJDQJLPHQJGH
$6$./$66($6$ $PHULFDQ6RFLHW\RI$QHVWKHVLRORJLVWV
$6$NODVVH)ULVNHSDVLHQWHUVRPU¡\NHUPLQGUHHQQVLJDUHWWHUGDJOLJ
$6$NODVVH3DVLHQWHUPHGHQDV\PSWRPDWLVNWLOVWDQGVRPEHKDQGOHVPHGLNDPHQWHOWIHNVK\SHUWHQVMRQ
HOOHUPHGNRVWIHNVGLDEHWHVPHOOLWXVW\SHRJHOOHUVIULVNHSDVLHQWHUVRPU¡\NHUVLJDUHWWHUHOOHUPHUGDJOLJ
$6$NODVVH3DVLHQWHUPHGHQWLOVWDQGVRPNDQJLV\PSWRPHUPHQVRPKROGHVXQGHUNRQWUROOPHGLNDPHQWHOW
IHNVPRGHUDWDQJLQDSHFWRULVRJPLOGDVWPD
$6$NODVVH3DVLHQWHUPHGHQWLOVWDQGVRPLNNHHUXQGHUNRQWUROOIHNVKMHUWHVYLNWRJDVWPD
$6$NODVVH0RULEXQGG¡HQGHSDVLHQW
0,1,,19$6,9.,585*,0,6 0LQLPDOO\,QYDVLYH6XUJHU\
0HG0,6PHQHVKHUDWNLUXUJHQKDUEUXNWNRUWVQLWWRJDWGHWHUEUXNWVSHVLDOLQVWUXPHQWODJHWIRU0,6
6<67(0,6.$17,%,27,.$
+HUI¡UHVGHWSnKYLONHWDQWLELRWLNXPVRPHUEOLWWEHQ\WWHWLIRUELQGHOVHPHGRSHUDVMRQHQIHNV0HGNDPHQW.HIOLQJ[PHGYDULJKHWWLPHU
7520%26(352)</$.6(
0HGLNDPHQWGRVHRJDQWDWWYDULJKHWDYSURI\ODNVHQVNDODQJLVVHSDUDWIRURSUHUDVMRQVGDJHQRJVHQHUH'HWVNDORJVnRSSJLVRPSDVLHQWHQVWnUIDVWSn
DQWLNRDJXODQWLD$OE\O(0DUHYDQ3ODYL[RO
),%5,12/<6(+(00(5
+HUI¡UHVGHWSnRPHQEHQ\WWHUEO¡GQLQJVUHGXVHUHQGHOHJHPLGOHULIRUELQGHOVHPHGRSHUDVMRQHQIHNV&\NORNDSURQ
%(,17$39('5(9,6-21
)HPXU3DSURVN\CVNODVVLILNDVMRQ
7\SH,0LQLPDOWWDSDYPHWDI\V UWEHQRJLQWDNWGLDI\VH
7\SH,,6WRUWWDSDYPHWDI\V UWEHQPHQLQWDNWGLDI\VH
7\SH,,,$%HW\GHOLJWDSDYPHWDI\V UWEHQXWHQPXOLJKHWIRUSUR[LPDOPHNDQLVNVW¡WWH2YHUFPLQWDNWFRUWLFDOLVLLVWKPXVRPUnGHW
7\SH,,,%%HW\GHOLJWDSDYPHWDI\V UWEHQXWHQPXOLJKHWIRUSUR[LPDOPHNDQLVNVW¡WWH8QGHUFPLQWDNWFRUWLFDOLVLLVWKPXVRPUnGHW
7\SH,9%HW\GHOLJWDSDYPHWDI\V UWEHQXWHQPXOLJKHWIRUSUR[LPDOPHNDQLVNVW¡WWH%UHGLVWKPXVPHGOLWHQPXOLJKHWIRUFRUWLFDOVW¡WWH
$FHWDEXOXP3DSURVN\CVNODVVLILNDVMRQ
7\SH,+HPLVI ULVNDFHWDEXOXPXWHQNDQWGHIHNWHU,QWDNWEDNUHRJIUHPUHNRORQQH'HIHNWHULIRUDQNULQJVKXOOVRPLNNH¡GHOHJJHUVXEFKRQGUDOEHQSODWH
7\SH,,$+HPLVI ULVNDFHWDEXOXPXWHQVWRUHNDQWGHIHNWHULQWDNWEDNUHRJIUHPUHNRORQQHPHQPHGOLWHPHWDI\V UWEHQLJMHQ
7\SH,,%+HPLVI ULVNDFHWDEXOXPXWHQVWRUHNDQWGHIHNWHULQWDNWEDNUHRJIUHPUHNRORQQHPHQPHGOLWHPHWDI\V UWEHQLJMHQRJQRHPDQJOHQGHVW¡WWHVXSHULRUW
7\SH,,&+HPLVI ULVNDFHWDEXOXPXWHQVWRUHNDQWGHIHNWHULQWDNWEDNUHRJIUHPUHNROORQQHPHQPHGGHIHNWLPHGLDOYHJJ
7\SH,,,$%HW\GHOLJNRPSRQHQWYDQGULQJRVWHRO\VHRJEHQWDS%HQWDSIUDNOWLO
7\SH,,,%%HW\GHOLJNRPSRQHQWYDQGULQJRVWHRO\VHRJEHQWDS%HQWDSIUDNOWLO
.RSLEHKROGHVWLOSDVLHQWMRXUQDOHQRULJLQDOHQVHQGHV+DXNHODQGXQLYHUVLWHWVVMXNHKXV
.RQWDNWSHUVRQHUYHGU¡UHQGHUHJLVWUHULQJVVNMHPDHU
2YHUOHJH/HLI,YDU+DYHOLQWOIRJNOLQLNNRYHUOHJH2YH)XUQHVWOI
2UWRSHGLVNNOLQLNN+DXNHODQGXQLYHUVLWHWVVMXNHKXV%HV¡NVDGUHVVH0¡OOHQGDOVEDNNHQ
6HNUHW UHUL1DVMRQDOW5HJLVWHUIRU/HGGSURWHVHU2UWRSHGLVNNOLQLNN+HOVH%HUJHQ
,QJXQQ9LQGHQHVWOIRJ5XWK:DVPXWKWOI
(SRVWQUO#KHOVHEHUJHQQR
,QWHUQHWKWWSZZZKDXNHODQGQRQUO
